A new antibody treatment from Immunovant and Roivant Sciences has demonstrated significant reductions in symptoms and disease activity for patients with generalized myasthenia gravis. In a Phase 3 clinical trial, the treatment batoclimab showed promising results, with improvements of 4.7 and 5.6 points on a patient-reported scale compared to a placebo, which had a 3.6-point improvement. The findings were deemed statistically significant by both low and high doses of batoclimab. CEO Matt Gline from Roivant praised the treatment’s efficacy data, citing “fantastic” results in terms of dose response and overall effectiveness.
Source: https://www.statnews.com/2025/03/19/immunovant-roivant-batoclimab-myasthenia-gravis-autoimmune-trial-success